• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Safety and Effectiveness of Tranexamic Acid in Cardiac Surgery Patients

August 10, 2022

Tranexamic acid is an antifibrinolytic agent that is commonly used to control bleeding in patients undergoing cardiac surgery.  Limited randomized controlled trial data, however, are available to determine the optimal dose.  High doses of tranexamic acid have been associated with seizures and thrombotic events.  In order to determine the optimal dose, the multicenter, double-blind Outcome Impact of Different Tranexamic Acid Regimes in Cardiac Surgery with Cardiopulmonary Bypass (OPTIMAL) trial compared high- (30 gm/kg initial bolus, 16 mg/kg/h maintenance dose during surgery, and 2 mg/kg pump prime dose) and low-doses of tranexamic acid (10 mg/kg initial bolus, 2 mg/kg/h maintenance dose, and 1 mg/kg prime dose).  The study enrolled 3079 patients (mean age, 52.8 years; 38.1% female) from 2018 to 2021; 333 of 1525 patents (21.8%) in the high dosage group received red blood cell (RBC) transfusions compared to 391 of 1506 patients (26.0%) in the low dose group (p=0.004).  The safety profile of high doses of tranexamic acid was noninferior to low doses.  A composite safety endpoint (30-day mortality, seizure, kidney dysfunction, and thrombotic events) was similar in both groups—17.6% in the high-dose group compared to 16.8% in the low dose group.  A higher dose of tranexamic acid modestly reduced the need for RBC transfusions in patients undergoing cardiac surgery and met the criteria for noninferiority for safety.  Further trials comparing tranexamic acid dosage in other populations are needed to confirm these findings.

Reference:

Shi J, Zhou C, Pan W, Sun H, et al.  Effect of High- vs Low Dose Tranexamic Acid infusion on need for red blood cell transfusion and adverse events in patients undergoing cardiac surgery.  JAMA 2022; 328(4); 336-347.

Filed Under

  • News
  • RBC Transfusion

Recommended

  • Delayed Umbilical Cord for Cesarean Deliveries Does Not Increase Maternal Blood Loss

  • A New Drug for Patients with Thrombotic Thrombocytopenic Purpura

  • Aspirin Increases Bleeding Risk

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Directed Blood Donations Should be Limited

  • Babesia Infection Reduces Red Cell Deformability

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley